Literature DB >> 15297412

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.

Jun Konishi1, Koichi Yamazaki, Miyuki Azuma, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Masaharu Nishimura.   

Abstract

PURPOSE: B7-H1/PD-L1 (B7-H1) and B7-DC/PD-L2 (B7-DC) are ligands for the receptor PD-1, which is known to negatively regulate T-cell activation. In the present study, we investigated the expression of B7-H1 and B7-DC in tumor specimens of non-small cell lung cancer and their relationships with clinicopathological variables and postoperative survival. Furthermore, we examined the correlation between B7-H1 expression on tumor cells and the number of tumor-infiltrating lymphocytes (TILs) or PD-1 expression on TILs. EXPERIMENTAL
DESIGN: The expression of B7-H1 and B7-DC in 52 surgically resected specimens of non-small cell lung cancer was evaluated immunohistochemically.
RESULTS: Expression of B7-H1 and B7-DC was focally observed in all non-small cell lung cancer tumor specimens. No relationship was found between the expression of B7-H1 or B7-DC and clinicopathological variables or postoperative survival. However, in the same sections evaluated, significantly fewer TILs were identified in B7-H1-positive tumor regions than in B7-H1-negative tumor regions in a subset of five patients (P = 0.01). Moreover, the percentage of TILs expressing PD-1 was significantly lower in B7-H1-positive tumor regions than in B7-H1-negative tumor regions (P = 0.02).
CONCLUSIONS: The expression of B7-H1 on tumor cells in local areas reciprocally correlated with the number of TILs, and this may contribute to negative regulation in antitumor immune responses in non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297412     DOI: 10.1158/1078-0432.CCR-04-0428

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  306 in total

Review 1.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

2.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

3.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

Review 4.  Role of PD-L1 and PD-L2 in allergic diseases and asthma.

Authors:  A K Singh; P Stock; O Akbari
Journal:  Allergy       Date:  2010-08-17       Impact factor: 13.146

5.  PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.

Authors:  Ze-Jun Zhou; Ping Zhan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 6.  Inhibitory costimulation and anti-tumor immunity.

Authors:  Natalia Martin-Orozco; Chen Dong
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

Review 7.  Immune checkpoint inhibitors in gastrointestinal malignancies.

Authors:  Vishal Jindal
Journal:  J Gastrointest Oncol       Date:  2018-04

8.  Programmed death ligand-1 expression in non-small cell lung cancer.

Authors:  Vamsidhar Velcheti; Kurt A Schalper; Daniel E Carvajal; Valsamo K Anagnostou; Konstantinos N Syrigos; Mario Sznol; Roy S Herbst; Scott N Gettinger; Lieping Chen; David L Rimm
Journal:  Lab Invest       Date:  2013-11-11       Impact factor: 5.662

9.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

10.  Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

Authors:  Cuiling Zhou; Gang Che; Xiaobin Zheng; Junlan Qiu; Zhinan Xie; Yunyan Cong; Xiaofeng Pei; Hongyu Zhang; Huanhuan Sun; Haiqing Ma
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.